Devraj Basu, MD, PhD, FACS
@basulab1.bsky.social
Cancer surgeon-scientist @PennMedicine. Our lab advances therapy for #headandneckcancer #HPV #hnscm. Opinions my own. Patient appointments 2156153534.
We recently defined the gene expression profiles distinguishing HPV+ OPSCCs that are prone to recur after TORS-based therapy. These the tumor-intrinsic and immune-related traits were tightly interrelated and generalizeable to nonsurgical cases as well. academic.oup.com/jnci/advance...
Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer
AbstractBackground. Limited understanding of the biology predisposing certain human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinomas (O
academic.oup.com
March 31, 2025 at 12:23 AM
We recently defined the gene expression profiles distinguishing HPV+ OPSCCs that are prone to recur after TORS-based therapy. These the tumor-intrinsic and immune-related traits were tightly interrelated and generalizeable to nonsurgical cases as well. academic.oup.com/jnci/advance...
Reposted by Devraj Basu, MD, PhD, FACS
This week I want to highlight the Phase ½ trial of alisertib + pembro led by Faye Johnson. It highlights the challenges in translating lab studies into patients. 🧪🧵
aacrjournals.org/clincancerre...
aacrjournals.org/clincancerre...
Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Abstract. Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition...
aacrjournals.org
December 4, 2024 at 4:55 PM
This week I want to highlight the Phase ½ trial of alisertib + pembro led by Faye Johnson. It highlights the challenges in translating lab studies into patients. 🧪🧵
aacrjournals.org/clincancerre...
aacrjournals.org/clincancerre...
Reposted by Devraj Basu, MD, PhD, FACS
This week’s post is from the Brakenhoff lab, and examines the copy number quite subtype of head and neck cancer. This is a genomically and biologically distinct subtype of HNSCC that is a strong candidate for more personalized therapy. 🧪🧵
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Hallmarks of a genomically distinct subclass of head and neck cancer - Nature Communications
HPV-negative head and neck squamous cell carcinomas (HNSCCs) are generally characterized by many copy number alterations (CNAs) and mutations. Here, the authors characterize a subgroup of HPV-negative...
www.nature.com
November 25, 2024 at 6:22 PM
This week’s post is from the Brakenhoff lab, and examines the copy number quite subtype of head and neck cancer. This is a genomically and biologically distinct subtype of HNSCC that is a strong candidate for more personalized therapy. 🧪🧵
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Devraj Basu, MD, PhD, FACS
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 25, 2024 at 8:43 PM
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang